GoHealthcare Practice Solutions

Sacral Transforaminal Epidural Steroid Injection

Medical Necessity, Prior Authorization, Documentation, Coding, Reimbursement, and Denial Prevention

Request HelpView Case Studies

GoHealthcare Results

Company-reported operational performance across specialty prior authorization and healthcare practice support engagements.

Procedure FamilyPrimary Procedure Name

Epidural ProceduresSacral Transforaminal Epidural Steroid Injection

Results vary by client, payer, specialty, case mix, and contracted scope.

Request HelpExplore Case Studies

Case Study Library: https://www.gohealthcarellc.com/case-studies.html

Procedure Navigation

Select a section to review clinical, policy, coding, documentation, reimbursement, or operational requirements.

Sections 1-10

1. Overview
2. Evidence at a Glance
3. Procedure Overview
4. Relevant Anatomy
5. Clinical Indications
6. Patient Selection
7. Contraindications and Precautions
8. Medical Necessity
9. Conservative Treatment Requirements
10. Diagnostic Prerequisites and Care-Pathway Sequencing

Sections 11-20

1. CMS National Coverage Determinations and National Guidance
2. Medicare LCDs and MAC Guidance
3. Medicare Billing and Coding Articles
4. CMS WISeR Model: Prior Authorization and Prepayment Review
5. Commercial Payer Policies
6. Blue Cross Blue Shield Policy Perspective
7. Delegated Utilization Management Guidelines
8. Evidence-Based Clinical and Specialty-Society Guidelines
9. Policy and Guideline Comparison Matrix
10. Prior Authorization Workflow

Sections 21-30

1. Clinical Documentation Requirements
2. Documentation Pearls
3. CPT and HCPCS Coding
4. ICD-10-CM Crosswalk
5. Modifiers, Units, NCCI, MUE, and Place of Service
6. Reimbursement Considerations
7. Integrated Compliance and Quality Controls
8. Denial Prevention
9. Common Denial Reasons
10. Appeals and Peer-to-Peer Review

Sections 31-40

1. Operational Workflow
2. Payer Perspective
3. Clinical Pearls
4. GoHealthcare Perspective
5. GoHealthcare Insights
6. Key Takeaways
7. Frequently Asked Questions
8. Related Procedures
9. References and Policy Sources
10. Disclaimer

1

Procedure Library

Overview

Lumbar transforaminal epidural steroid injection is an image-guided epidural procedure that delivers medication through a lumbar or sacral neural foramen toward a selected nerve root. It is generally used for radicular pain, radiculopathy, or selected neurogenic claudication when the clinical pattern and diagnostic findings identify a specific lumbar or sacral level and the applicable coverage criteria are met. The procedure is reported with CPT 64483 for the first lumbar or sacral level and add-on CPT 64484 for an additional level when performed and supported.

Operationally, sacral TFESI is a level-specific and laterality-specific procedure. The authorization file must identify the exact sacral root, side, symptom distribution, examination findings, imaging lesion, prior treatment, and route rationale. The documentation must also distinguish a sacral TFESI from a caudal epidural injection, lumbar interlaminar epidural injection, sacroiliac joint injection, and diagnostic selective nerve root block.

The evidence position is diagnosis-dependent. Evidence is strongest for radicular pain associated with lumbar disc herniation and less favorable for lumbar spinal stenosis. This distinction matters during authorization and peer-to-peer review. A generalized appeal that cites strong sacral TFESI evidence without identifying the treated diagnosis can overstate the literature and undermine credibility.

Do Not Promise a Series Sacral TFESI should not be scheduled or represented as an automatic series of three. Medicare and major commercial policies require each repeat session to be justified by the documented response, timing, regional utilization history, and current policy.

Back to procedure navigation

2

Procedure Library

Evidence at a Glance

Domain	Operational conclusion	Primary authority
Medicare NCD	No procedure-specific National Coverage Determination governs sacral TFESI. Coverage is primarily controlled by MAC LCDs, billing articles, Medicare manuals, and general reasonable-and-necessary rules.	CMS and MAC policy
Medicare LCD	Aligned LCDs commonly require concordant history, examination and imaging; qualifying radicular pain, radiculopathy, or neurogenic claudication; significant functional impact; >=4 weeks of symptoms and conservative care; image guidance with contrast; active rehabilitation; response-based repeats; and <=4 ESI sessions per region in a rolling 12 months.	CMS LCD L36920 and aligned LCD family
Levels and laterality	Medicare generally permits lumbar/sacral TFESI at no more than two total levels in one spinal region per session. Bilateral treatment is permitted only when clinically indicated and documented.	MAC LCD and billing article
Coding	64483 reports the first lumbar or sacral transforaminal level. +64484 is an add-on code for each additional level. T12-L1 transforaminal injection is reported with 64479, not 64483.	MAC billing article
Diagnosis variation	The covered ICD-10-CM list varies by MAC article. A key example is M48.07: included by A56651 but absent from A58995, while M48.062 is included in both.	MAC billing articles A56651 and A58995
Commercial and delegated UM	Most plans require authorization, level-specific symptoms, imaging concordance, conservative care, fluoroscopy/CT with contrast, and response-based repeat criteria. Exact thresholds and session limits vary.	UHC, Aetna, Carelon, eviCore, plan-specific Cohere/Evolent
Clinical evidence	AAN 2025 found modest short-term benefit for radiculopathy and limited evidence for long-term benefit; it found no significant outcome difference between approaches in available comparisons. ASIPP reports Level I evidence for disc-herniation radicular pain but a substantially weaker Level IV-III position for spinal stenosis.	AAN and ASIPP
Safety	Epidural corticosteroid use is off-label. Rare serious neurologic events are recognized. Consensus recommendations favor non-particulate steroid for the initial sacral TFESI, while recognizing selected situations in which particulate steroid may be considered by the treating physician.	FDA communication and multidisciplinary consensus
Primary denial risk	Level/laterality mismatch, missing imaging concordance, insufficient route rationale, incomplete conservative-care dates, regional frequency miscount, or inadequate prior-response documentation.	GoHealthcare operational analysis

Back to procedure navigation

3

Procedure Library

Procedure Overview

The transforaminal route is a targeted epidural approach directed toward a selected exiting or traversing nerve root through the neural foramen. The treating physician determines the route, level, side, injectate, and procedural plan based on the patient's presentation, imaging, anatomy, prior treatment, prior surgery, and risk profile. This resource does not provide needle-placement instruction or procedural training.

Operational distinctions

• Therapeutic sacral TFESI. The procedure is intended to reduce inflammation and symptoms associated with a qualifying lumbar or sacral radicular condition.
• Diagnostic selective nerve root block. This may be coded with the same transforaminal code family but serves a different diagnostic purpose. Certain Medicare articles direct use of modifier KX for a diagnostic selective nerve root block. The order, authorization, note, and claim must identify the intended purpose.
• Lumbar interlaminar ESI. This uses a different approach and code family. It may be clinically reasonable but is not interchangeable with a transforaminal authorization.
• Caudal ESI. This is a lumbosacral epidural approach through the sacral hiatus and is reported differently. It may provide broader epidural distribution but is not a substitute on the claim for an authorized TFESI.
• Sacral TFESI. Sacral transforaminal injections remain within the 64483/64484 lumbar-or-sacral code family. The actual level and side must be documented and authorized.

Approach Clause Every sacral TFESI note should contain a concise patient-specific explanation of why the transforaminal route is appropriate. The strongest clause links a named nerve root and concordant foraminal or lateral recess pathology to the patient's dermatomal symptoms, examination, and planned functional objective.

Back to procedure navigation

4

Procedure Library

Relevant Anatomy

Lumbar and sacral nerve roots exit through neural foramina formed by adjacent vertebral structures. Foraminal stenosis, disc herniation, osteophytes, degenerative change, and postoperative changes may irritate or compress a specific nerve root. The transforaminal route is selected when targeted epidural delivery adjacent to that root is clinically appropriate.

For authorization purposes, anatomy must be translated into a coherent level and laterality story. The symptom distribution, neurologic examination, and imaging report should identify the same root or explain any apparent discrepancy. General findings such as "multilevel degenerative disease" or "disc bulges" are not enough without clinical correlation.

Documentation element	Operational expectation
Named nerve root	Identify the suspected lumbar or sacral root when the evidence supports it.
Level	Order, authorization, schedule, procedure note, and claim must use the same level terminology.
Laterality	Right, left, or bilateral symptoms and findings should match the requested service.
Imaging lesion	Record the relevant disc herniation, foraminal stenosis, lateral recess stenosis, osteophyte complex, or postoperative finding.
Clinical correlation	Explain how the lesion reasonably accounts for the symptom and examination pattern.
T12-L1 boundary	Recognize the coding boundary: TFESI at T12-L1 is reported with 64479 under MAC billing guidance.

Back to procedure navigation

5

Procedure Library

Clinical Indications

Coverage is generally strongest when the patient has function-limiting lumbosacral radicular pain or radiculopathy in a documented sacral distribution, the imaging demonstrates a concordant lesion affecting the requested sacral root, conservative care requirements are satisfied or an exception is documented, and the requested level, side, and approach match the record. Isolated axial low-back pain, nonspecific buttock pain, sacroiliac joint pain, or peripheral neuropathy without a supported radicular generator is commonly insufficient.

• Lumbar disc herniation with radicular pain. This is the strongest evidence position for sacral TFESI when the symptoms, examination, and imaging identify a concordant root.
• Lumbar or sacral radiculopathy. Objective motor, sensory, or reflex findings strengthen the case and may be required by some UM guidelines.
• Foraminal or lateral recess stenosis. A targeted route may be reasonable when imaging and symptoms identify the affected root; evidence for stenosis is less favorable than for disc herniation.
• Neurogenic claudication. The record should define walking or standing tolerance, imaging severity, and functional impact. Some policies may favor or more strongly support another approach.
• Post-laminectomy or persistent spinal pain after surgery. The note should identify a current radicular generator rather than relying on the postoperative status alone.
• Facet synovial cyst with nerve-root compression. Some delegated UM policies permit a TFESI in connection with synovial cyst aspiration when explicit criteria are met.
• Acute herpes zoster-associated radicular pain. This is recognized in certain Medicare LCDs but must be verified against the governing policy and clinical circumstances.

Coverage Vulnerability Nonspecific axial low-back pain, discogenic pain without radicular features, generalized degenerative findings, or an imaging abnormality that does not match the requested level and side is frequently noncovered or denied.

Back to procedure navigation

6

Procedure Library

Patient Selection

Appropriate selection requires a complete clinical episode, not a favorable code. The record should show that the patient's symptoms, neurologic findings, imaging, functional limitations, prior treatment, requested level and laterality, route rationale, and follow-up plan are mutually consistent.

Selection element	What the record should show	Reviewer question
Radicular pattern	Dermatomal leg pain, paresthesia, dysesthesia, weakness, or another level-specific pattern.	Is there a named root and a clinically plausible distribution?
Objective findings	Motor, sensory, or reflex change when present; relevant provocative or functional findings.	Does the examination support radiculopathy or only generalized pain?
Imaging concordance	MRI or CT finding that explains the involved root and side.	Does the level and laterality match the request?
Functional impairment	Specific limits in walking, standing, sleep, work, self-care, or rehabilitation with baseline measurement.	Is the impairment clinically significant and measurable?
Conservative-care history	Dated treatment, adherence, failure, intolerance, or contraindication.	Could an auditor determine exactly what was tried and for how long?
Approach rationale	Patient-specific reason for targeted transforaminal access.	Why not interlaminar or caudal for this presentation?
Response plan	Same pain or function scale to be repeated after the injection.	How will the result change the next clinical decision?

Back to procedure navigation

7

Procedure Library

Contraindications and Precautions

The treating physician must assess contraindications and risks under current clinical standards, patient-specific conditions, medication guidance, and facility policy. Authorization staff should identify missing clinical documentation but should not provide medication-hold or procedural instructions.

• Infection. Active systemic infection, local infection, suspected discitis, osteomyelitis, or epidural infection requires clinical evaluation and may preclude an elective injection.
• Urgent neurologic findings. Progressive motor loss, cauda equina symptoms, bowel or bladder dysfunction, saddle anesthesia, or other red flags require escalation rather than routine authorization.
• Bleeding risk. Anticoagulant and antiplatelet management requires individualized clinician coordination using current specialty guidance.
• Allergy and contrast risk. Relevant contrast, medication, antiseptic, or latex allergies and the alternative plan should be documented.
• Pregnancy. Imaging and medication decisions require physician assessment and facility protocol.
• Corticosteroid exposure. Diabetes, osteoporosis risk, immune suppression, prior steroid exposure, and systemic effects may require additional risk-benefit documentation.
• Sedation. Moderate or deep sedation, general anesthesia, or monitored anesthesia care is not routinely considered necessary by Medicare LCDs; a patient-specific exception must be documented.
• Vascular and neurologic safety. The transforaminal route has recognized rare catastrophic risks. Clinical governance should address image guidance, contrast use, injectate selection, emergency readiness, informed consent, and credentialing.

Back to procedure navigation

8

Procedure Library

Medical Necessity

Medical necessity is the integrated explanation for why a targeted lumbar or sacral TFESI is reasonable and necessary now. It should be evident in the physician note before the authorization team submits the case. A templated checklist may support completeness, but it cannot substitute for clinical reasoning.

Core elements

• Qualifying diagnosis and symptoms. The condition must be recognized by the governing policy and supported by the record.
• Anatomic concordance. The named root, level, laterality, symptoms, examination, and imaging should align.
• Functional impact. Document significant activity or quality-of-life limitation using a baseline pain or functional measure.
• Duration and prior care. Meet the applicable duration and conservative-treatment requirements or document a policy-recognized exception.
• Targeted-route rationale. Explain why transforaminal access is appropriate for this lesion and clinical pattern.
• Image-guidance plan. Fluoroscopy or CT with contrast is expected by Medicare and most major policies, subject to documented exceptions.
• Measurable objective. State what pain, function, medication, or rehabilitation improvement is expected.
• Regional utilization check. Count all ESI approaches within the lumbar/sacral region during the policy period.
• Repeat justification. For a repeat injection, quantify the prior response using the same scale and satisfy the payer's timing and duration threshold.

Clinical Coherence Test Before submission, a reviewer should be able to answer six questions without inference: What root? What level? What side? What lesion? What failed? Why this route now?

Back to procedure navigation

9

Procedure Library

Conservative Treatment Requirements

At least four weeks of noninvasive conservative care is a common requirement across Medicare, UnitedHealthcare, Aetna, Carelon, and eviCore, although the components and exceptions differ. Documentation should contain dates, treatment type, participation or adherence, response, intolerance, contraindication, and the reason an injection is appropriate despite incomplete improvement.

Conservative-care component	Documentation standard
Medication management	Names or classes, dates, response, adverse effects, contraindication, or patient-specific reason not used.
Physical therapy or supervised exercise	Dates, attendance, home program, objective progress, and reason continued symptoms limit function.
Home exercise program	Specific program and participation; avoid a bare statement that HEP was "failed."
Activity modification	What was modified and whether function remained impaired.
Other noninvasive care	Chiropractic care, cognitive or behavioral support, education, or other relevant modalities when part of the payer pathway.
Exception	Document objective neurologic deficit, severe presentation, intolerance, contraindication, or another policy-defined reason for an abbreviated pathway.

Carelon Exception Carelon may permit the conservative-care period to be reduced from four weeks to two weeks when there is clear objective evidence of radiculopathy. The record must contain the qualifying findings; do not assume pain alone meets this exception.

Back to procedure navigation

10

Procedure Library

Diagnostic Prerequisites and Care-Pathway Sequencing

Sacral TFESI is therapeutic unless the clinician intentionally performs a diagnostic selective nerve root block. A separate diagnostic block is not universally required before therapeutic TFESI. The pathway instead depends on clinical evaluation, level-specific findings, imaging or electrodiagnostic support when required, conservative care, and a treatment plan that connects temporary symptom relief to function or rehabilitation.

Imaging requirements

• Medicare. The LCD requires concordant radiological testing as part of the medical-necessity record and fluoroscopy or CT with contrast for the procedure, subject to limited exceptions.
• UnitedHealthcare. Requires imaging or electrodiagnostic evidence of structural or functional nerve-root involvement that corresponds to symptoms.
• Carelon. Requires MRI or CT evidence correlating with the symptoms for transforaminal injection; the no-advanced-imaging pathway described for selected interlaminar or caudal cases does not apply to TFESI.
• eviCore/Cigna. Current CMM-200 criteria use level-specific neurologic findings and/or MRI, CT, or electrodiagnostic evidence; transforaminal procedures require current supporting information under the guideline.
• Aetna. Requires clinical and diagnostic support under its transforaminal and back-pain policies; verify the member-specific effective policy.

Treatment sequencing

• Initial injection. Establish baseline pain and function, target level and side, and route rationale.
• Early repeat after inadequate initial response. Medicare may allow a second injection after 14 days using a different approach, level, or medication when clinically appropriate and clearly documented. This is not authorization for an automatic repeat.
• Repeat after benefit. Meet the applicable threshold for magnitude and duration of pain and/or functional improvement.
• Failure of repeated injections. Reassess diagnosis, anatomy, route, rehabilitation, medication strategy, surgical indications, and alternative interventions rather than continuing without measurable benefit.
• Long-term use. Medicare coverage beyond 12 months requires additional criteria, rationale, sustained benefit, and primary-care notification under aligned LCDs.

Back to procedure navigation

11

Procedure Library

CMS National Coverage Determinations and National Guidance

There is no procedure-specific CMS National Coverage Determination for sacral TFESI. Original Medicare coverage is therefore governed through the applicable MAC LCD and billing article, together with Medicare statutes, manuals, coding rules, program-integrity requirements, and general reasonable-and-necessary standards. The absence of an NCD does not mean unrestricted coverage.

National source	Operational relevance
Social Security Act Section 1862(a)(1)(A)	Services must be reasonable and necessary for diagnosis or treatment.
Medicare Claims Processing Manual	Controls general claim submission, modifier, place-of-service, and documentation principles.
Medicare Program Integrity Manual	Supports medical review, documentation requests, and contractor review activity.
FDA safety communication	Warns of rare serious neurologic events after epidural corticosteroid injection and notes that epidural corticosteroid use is not FDA-approved.
CMS WISeR Model	Introduces optional prior authorization or prepayment review for selected services and states in selected model materials; see Section 14 for the code-list inconsistency relevant to TFESI.

Back to procedure navigation

12

Procedure Library

Medicare LCDs and MAC Guidance

A family of aligned MAC LCDs titled "Epidural Steroid Injections for Pain Management" controls Original Medicare coverage in many jurisdictions. Common examples include L36920, L33906, L38994, L39015, L39036, L39054, and L39240. The specific controlling LCD depends on the beneficiary's jurisdiction, provider, and date of service. Always use the live MCD version and the linked article for that MAC.

Common LCD requirements

Requirement	Operational standard
Covered condition	History, examination, and concordant imaging supporting radiculopathy, radicular pain, and/or neurogenic claudication due to disc herniation, osteophyte or osteophyte complex, or severe degenerative disc disease causing foraminal or central stenosis; or post-laminectomy syndrome; or acute herpes zoster-associated pain.
Severity and function	Pain or symptoms must significantly affect quality of life or function. Record a baseline pain or functional scale and use the same scale at follow-up.
Duration and conservative care	Generally >=4 weeks of pain and inability to tolerate or failure of >=4 weeks of noninvasive conservative care, with a zoster exception recognized in the LCD.
Image guidance	Fluoroscopy or CT with contrast. Ultrasound without contrast is considered only for documented contrast allergy or pregnancy under the LCD.
Levels	No more than two total transforaminal levels in one spinal region per session.
Laterality	Bilateral TFESI only when clinically indicated and documented.
Repeat after benefit	Generally requires >=50% sustained improvement in pain and/or function from baseline using the same scale for at least three months.
Early repeat after underperformance	A repeat after 14 days may be considered with a different approach, level, or medication and documented rationale.
Frequency	No more than four ESI sessions per spinal region in a rolling 12 months, counting interlaminar, caudal, and transforaminal approaches together.
Other controls	One spinal region per session; no predetermined series; active rehabilitation or home exercise; lowest effective steroid dose; routine moderate/deep sedation or MAC is generally not reasonable and necessary.
Beyond 12 months	Requires sustained >=50% benefit, severe functional disability, a documented rationale for continuing ESI, and notification of the primary care clinician under aligned LCDs.

Regional Counting Trap Lumbar interlaminar ESI, caudal ESI, and lumbar/sacral TFESI draw from the same lumbar/sacral regional utilization pool under aligned Medicare LCDs. Counting each approach separately creates audit and denial exposure.

Back to procedure navigation

13

Procedure Library

Medicare Billing and Coding Articles

The billing article is the operational companion to the LCD. It identifies covered ICD-10-CM codes, code-specific instructions, modifier expectations, utilization parameters, and documentation requirements. Two commonly encountered articles are A56651 and A58995, but practices must identify the article linked to the patient's current LCD.

Article issue	Operational rule
Primary and add-on codes	64483 reports the first lumbar or sacral transforaminal level. 64484 is reported in addition for each additional level when performed and medically necessary.
T12-L1	A TFESI at T12-L1 is reported with 64479 under MAC article guidance.
Maximum levels	Only two total transforaminal levels per session are allowed under aligned article parameters.
Unilateral billing	Report one line and one unit for a unilateral single level, subject to payer claim rules.
Bilateral billing	Professional claims commonly use modifier 50 according to payer instructions. ASC billing may require separate RT and LT lines rather than modifier 50. Verify the payer and setting rule.
Diagnostic SNRB	A diagnostic selective nerve root block uses the same code family; certain articles instruct use of modifier KX. Aberrant KX use is a stated medical-review risk.
Image guidance	Fluoroscopy or CT guidance is included in 64483/64484 and is not separately reported.
Frequency	The article repeats the four-session regional limit and one-region-per-session rules.
Diagnosis list	Covered diagnosis codes differ by article. Never copy one MAC's ICD list into a national template.

ICD Variation Alert M48.07, spinal stenosis, sacral region without neurogenic claudication, appears in A56651 but not in A58995. M48.062, lumbar stenosis with neurogenic claudication, appears in both. The same diagnosis may therefore process differently by MAC article.

Back to procedure navigation

14

Procedure Library

CMS WISeR Model: Prior Authorization and Prepayment Review

The WISeR Model applies in New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington for selected Original Medicare services from January 15, 2026 through December 31, 2031. Providers may use an optional prior-authorization pathway; claims submitted without an affirmed decision may be subject to prepayment medical review.

For epidural steroid injections, CMS Operational Guide Version 6.0 contains a material code-list inconsistency. Section 6.2.10 states that prior authorization and prepayment review are implemented for CPT 62323 only. Appendix Table A10 nevertheless lists 62321, 62323, 64479, 64480, 64483, and 64484. Because the operative narrative uses the word "only" while the appendix includes TFESI codes, practices should not infer the answer. Verify the current WISeR model entity instructions and live submission system for 64483/64484 before the date of service.

GoHealthcare Operational Control For every Original Medicare TFESI in a WISeR state, document a code-level WISeR applicability check. Save the guide version, portal result, model-entity confirmation when needed, and the decision in the authorization record. This prevents both missed reviews and unnecessary submissions.

Back to procedure navigation

15

Procedure Library

Commercial Payer Policies

Commercial and Medicare Advantage requirements are product-specific and may be delegated. The payer card on the front of the insurance card may not identify the organization that actually applies medical-necessity criteria. Verify the plan, network, benefit, delegated reviewer, policy title, version, effective date, and code scope before submission.

Organization	Current operational themes	Critical caution
UnitedHealthcare	Radicular pain supported by history/exam; >=4 weeks conservative care; structural or functional nerve-root involvement by imaging or electrodiagnostics; fluoroscopy or CT; response-based repeat criteria; up to four sessions per region per year.	Use the policy effective for the member's product. Commercial and Medicare Advantage policies may differ.
Aetna	Dedicated Transforaminal Epidural Injections policy plus broader back-pain policy; level-specific clinical and diagnostic support; conservative care; response-based repeat criteria; no more than two contiguous levels; session limits.	Aetna terminology for sessions, injections, bilateral levels, and repeat criteria must be read carefully.
Cigna/eviCore	CMM-200 governs many Cigna products; criteria include conservative care, comprehensive management, level-specific symptoms and findings, image guidance, level limits, and response-based repeats.	A new version may be published before its effective date. Use the version effective on the date of service.
Humana and other national plans	Often require prior authorization through an internal program or delegated vendor and use plan-specific criteria.	Do not generalize another payer's thresholds. Retrieve the current plan document.
Workers' compensation and liability	State treatment guidelines, carrier rules, utilization review, fee schedules, legal status, and authorization requirements may differ substantially.	Do not apply commercial or Medicare criteria automatically to workers' compensation or motor vehicle cases.

Back to procedure navigation

16

Procedure Library

Blue Cross Blue Shield Policy Perspective

Blue Cross Blue Shield is not one national medical policy. Each independent plan may maintain its own criteria, adopt a regional policy, use a vendor guideline, or delegate review. For example, Blue Cross NC has archived its plan-specific epidural policy and directs applicable interventional pain review to Carelon, while other Blue plans publish their own medical or reimbursement policies.

• Identify the exact Blue plan. The member's home plan, local plan, employer product, and BlueCard routing can affect the authorization pathway.
• Separate medical policy from claim policy. A reimbursement edit may allow or limit units differently from the medical-necessity guideline. Both must be checked.
• Confirm delegation. A Blue plan may use Carelon, eviCore, TurningPoint, or an internal UM team.
• Do not quote a sister plan as controlling. Another state plan's policy may provide context but does not govern the member.
• Save the live source. Retain the policy title, identifier, version, effective date, access date, and reviewer portal result.

Back to procedure navigation

17

Procedure Library

Delegated Utilization Management Guidelines

Carelon

Carelon's Interventional Pain Management guideline effective June 14, 2026 requires a qualifying radicular or claudication presentation with functional impairment and supporting examination. For transforaminal ESI, advanced imaging is required and should demonstrate a lesion that correlates with the level and side. Carelon generally requires four weeks of conservative care, with a possible reduction to two weeks when objective radiculopathy is clearly documented. Repeat injection criteria generally require >=50% pain reduction and functional improvement sustained for at least three months.

eviCore by Evernorth

CMM-200 effective February 25, 2026 requires at least four weeks of conservative treatment and participation in a comprehensive pain-management program for key indications. It requires fluoroscopic or CT guidance with contrast except when contraindicated. Therapeutic TFESI is limited to no more than two contiguous unilateral or bilateral levels in a session. The guideline permits up to three ESI sessions per episode and region in six months and no more than four per region in a rolling 12 months. A repeat requires at least 14 days since the prior ESI, >=50% relief of radicular pain for at least two weeks, and either improved function/activity or reduced medication or additional services. A later version is published with an August 4, 2026 effective date; use the version effective on the date of service.

Cohere Health

Cohere manages musculoskeletal prior authorization for selected health plans and its scope may include 64483 and 64484. Cohere does not publish one universal sacral TFESI criterion set that applies across every delegated plan. The authorization team must use the member-specific Cohere workflow, plan policy, questionnaire, and documentation prompts. Do not convert portal questions into a national policy statement.

Evolent / RadMD

Evolent and RadMD administer interventional pain review for selected health plans. The controlling guideline may be plan-specific and may require portal access. Verify the plan's current Evolent guideline, code scope, imaging requirements, conservative-treatment criteria, repeat thresholds, and regional frequency limits. A general Evolent guideline should not override a plan-specific document or state mandate.

Delegation Verification The first authorization question is not "What does the payer require?" It is "Who is making the medical-necessity decision for this member, code, plan, and date of service?"

Back to procedure navigation

18

Procedure Library

Evidence-Based Clinical and Specialty-Society Guidelines

Clinical evidence should be used accurately and by diagnosis. It informs medical decision-making and appeals but does not override a benefit plan or controlling policy. Avoid presenting clinical guideline grades as if they were universal coverage rules.

Source	Evidence position	Operational interpretation
AAN systematic review, 2025	ESIs probably provide modest short-term pain and disability benefit for radiculopathy; evidence for long-term pain benefit is insufficient. For lumbar stenosis, ESIs may modestly reduce disability but generally do not reduce pain. Comparative studies did not show significant outcome differences among techniques.	Use measured expectations. Do not claim that transforaminal injection is clinically superior to interlaminar or caudal based on the AAN review.
ASIPP comprehensive guidelines, 2021	Reports Level I evidence with a strong recommendation for sacral TFESI for disc-herniation radicular pain. For spinal stenosis, the transforaminal evidence position is Level IV to III with a moderate recommendation, weaker than other lumbar approaches.	Diagnosis drives the evidence argument. Disc herniation is the strongest position; stenosis needs careful route rationale and modest outcome claims.
Pain Physician TFESI systematic review, 2021	Reports Level I evidence for transforaminal injection in radicular pain due to disc herniation.	Useful for a diagnosis-specific appeal, not a blanket defense of every TFESI indication.
FDA safety communication, 2014	Warns of rare serious neurologic events and states corticosteroids are not FDA-approved for epidural administration.	Support informed consent, governance, and risk controls; do not misstate this as a coverage prohibition.
Multidisciplinary Safe Use consensus, 2015	Recommends real-time fluoroscopy or digital subtraction with contrast for sacral TFESI and favors non-particulate steroid for the initial injection; recognizes selected situations where particulate steroid may be used.	Document the injectate and safety rationale. The consensus is not identical to an FDA labeling mandate.
ACR-ASNR-ASSR-SIR-SNIS practice parameter, 2026	Emphasizes multidisciplinary care pathways, appropriate indications and contraindications, and performance by trained and credentialed physicians.	Use as a current clinical-governance and credentialing reference.

Evidence Discipline For disc herniation, sacral TFESI has a strong evidence argument. For spinal stenosis, avoid importing that stronger grade. The diagnosis, not the procedure name alone, determines the defensible evidence position.

Back to procedure navigation

19

Procedure Library

Policy and Guideline Comparison Matrix

Source	Initial criteria	Imaging/levels	Repeat and frequency
Medicare aligned LCDs	Qualifying radicular condition; significant function impact; >=4 weeks symptoms and conservative care.	Fluoroscopy/CT with contrast; up to two TF levels; bilateral if indicated.	Generally >=50% sustained improvement for >=3 months; early repeat after 14 days with changed plan and rationale; <=4 regional sessions/12 months.
UnitedHealthcare	Radicular pain; >=4 weeks conservative care; structural or functional nerve-root evidence.	Fluoroscopy/CT; level and side must correlate.	Criteria vary by response pattern; up to four sessions per region per year.
Aetna	Policy-specific therapeutic criteria and conservative care.	No more than two contiguous levels; verify bilateral terminology.	Repeat requires documented clinical benefit; up to three sessions/episode in six months and four/12 months under current policy structure.
Carelon	Radicular pain/radiculopathy/claudication with functional impairment; generally four weeks conservative care, possibly two with objective deficit.	MRI/CT required for TFESI and must correlate.	Generally >=50% pain reduction plus functional improvement sustained >=3 months; verify current session limits.
eviCore/Cigna	Four weeks conservative care plus comprehensive management and level-specific evidence.	Fluoroscopy/CT with contrast; <=2 contiguous TF levels.	>=14 days; >=50% relief for >=2 weeks plus functional or utilization improvement; <=3 sessions/6 months and <=4/12 months.
Cohere / Evolent	Plan-specific delegated criteria.	Portal and plan policy determine requirements.	Do not infer universal thresholds; verify live workflow.

Back to procedure navigation

20

Procedure Library

Prior Authorization Workflow

A high-performing workflow treats sacral TFESI as a code-, root-, level-, side-, diagnosis-, and policy-specific episode. The following sequence is designed to reduce avoidable peer-to-peer review, rescheduling, and authorization-to-claim mismatch.

1. Identify the payer, product, network, benefit, delegated UM organization, and authorization channel.

2. Confirm that CPT 64483 and, when planned, +64484 are in scope and determine whether bilateral treatment changes the submission method.

3. Identify the live policy, version, effective date, and date accessed. Save the source in the case record.

4. Confirm the diagnosis is supported by the governing ICD-10-CM article or policy and by the clinical record.

5. Validate the named root, level, side, symptom distribution, examination, and imaging concordance.

6. Confirm the duration and dated conservative-care pathway, including failure, intolerance, contraindication, and adherence.

7. Capture baseline pain and functional measures using tools that can be repeated after the procedure.

8. Confirm the physician's transforaminal route rationale and the planned rehabilitation or functional objective.

9. Count all lumbar/sacral ESI sessions, across all approaches, during the payer's look-back period.

10. For a repeat request, quantify prior pain relief, functional improvement, duration, medication change, and whether the same scale was used.

11. Confirm site of service, rendering provider, facility, date range, units, laterality, and all planned codes.

12. Submit only records that support the requested service; create an index or concise clinical summary when the payer permits.

13. Track status, requests for information, deadlines, peer-to-peer windows, and authorization expiration.

14. Reconcile the authorization against the scheduled and performed service before claim release.

15. Document the post-procedure outcome to support the next clinical decision and any future authorization.

Authorization Stop Rule Do not schedule a second level, bilateral service, or changed route on the assumption that the original authorization will cover it. Resolve the authorization before the procedure whenever clinically and operationally possible.

Back to procedure navigation

21

Procedure Library

Clinical Documentation Requirements

Initial request

Required domain	Documentation elements
History	Onset, duration, distribution, laterality, severity, aggravating factors, prior episodes, and relevant red flags.
Examination	Focused neurologic findings including strength, sensation, reflexes, gait, tension signs, and functional findings when clinically relevant.
Diagnosis	Specific radicular condition and suspected root; avoid relying only on generic low-back pain or degenerative disease.
Imaging	Date, modality, level, side, lesion, and explicit correlation with the clinical presentation.
Functional impact	Specific walking, standing, work, sleep, self-care, rehabilitation, or other limitations and a baseline scale.
Conservative care	Treatment type, start/end dates, participation, response, intolerance, contraindication, and continued impairment.
Approach rationale	Why targeted transforaminal access is appropriate instead of interlaminar or caudal.
Procedure plan	Lumbar or sacral level(s), laterality, image guidance, contrast plan, and clinical objective.
Utilization history	All ESI sessions in the lumbar/sacral region, regardless of route or provider when known.
Care plan	How the injection supports active rehabilitation, function, medication optimization, diagnostic clarification, or another next step.

Repeat request

• Same outcome instrument. Use the same pain or functional scale documented at baseline when the policy requires it.
• Magnitude of benefit. State the percentage improvement in pain and function, not only that the patient "did better."
• Duration. Document start and end dates or the duration of meaningful benefit.
• Functional change. Record walking, standing, sleep, work, self-care, rehabilitation participation, or medication use.
• Reason for repeat. Explain why another injection is reasonable now and how it fits the treatment plan.
• Changed plan after underperformance. If the first injection underperformed, document the changed approach, level, medication, or clinical rationale as required by the policy.

Back to procedure navigation

22

Procedure Library

Documentation Pearls

• Name the root, not just the region. "Right L5 radicular pain" is more operationally useful than "sacral radiculopathy" when the evidence supports that specificity.
• Quote the relevant imaging finding. Capture the exact level, side, and lesion rather than attaching an MRI without explaining concordance.
• Explain the route. A short approach clause prevents the reviewer from assuming the request is interchangeable with a lower-risk or differently supported route.
• Document laterality in every workflow object. The order, authorization, schedule, operative note, and claim should agree.
• Measure function. Walking tolerance, standing tolerance, sleep, work, and rehabilitation participation often communicate necessity better than pain score alone.
• Count the entire lumbar/sacral region. Interlaminar, caudal, and transforaminal sessions may share one regional limit.
• Do not copy forward old response language. Repeat criteria depend on current, patient-specific improvement and duration.
• Separate therapeutic TFESI from diagnostic SNRB. The purpose affects documentation, authorization, modifier use, and medical review.
• Preserve policy provenance. Save the actual policy version, not only a staff note saying "meets guidelines."

Back to procedure navigation

23

Procedure Library

CPT and HCPCS Coding

Coding must reflect the service actually performed, the anatomic region, number of levels, laterality, purpose, image guidance, setting, and payer rules. The following table is an operational overview, not a substitute for the current CPT codebook, NCCI manual, payer edits, or coding advice.

Code	Operational use	Key controls
64483	Lumbar or sacral transforaminal epidural injection, single level, with fluoroscopy or CT.	Primary code for the first sacral level, including a single S1 target. Image guidance is integral.
+64484	Each additional lumbar or sacral transforaminal level.	Add-on code; report with 64483 only when another medically necessary lumbar or sacral level is performed, documented, and authorized.
62323	Lumbar or sacral interlaminar or caudal epidural injection with imaging.	Different approach and code family; do not substitute for an approved sacral TFESI.
27096	Sacroiliac joint injection with image guidance.	Different anatomic target and clinical indication; not interchangeable with sacral TFESI.
J-codes as applicable	Medication may be separately reportable in some settings and contracts.	Verify drug, units, wastage, site, contract, and who supplies the medication.
KX modifier as directed	Some MAC articles use KX to identify a diagnostic selective nerve root block.	Do not append routinely to therapeutic TFESI; verify the governing article.

Coding Boundary T12-L1 is the code boundary most likely to create an avoidable error. Under MAC billing guidance, a transforaminal injection at T12-L1 is reported with 64479.

Back to procedure navigation

24

Procedure Library

ICD-10-CM Crosswalk

The ICD-10-CM code must represent the documented condition and appear on the governing payer or MAC list when a list is used. A code does not create medical necessity. It must be supported by the symptom pattern, examination, imaging, level, laterality, and treatment plan.

ICD-10-CM family or example	Clinical relationship	Operational caution
M54.17	Radiculopathy, lumbosacral region.	Common symptom code when the record supports a sacral-root syndrome; verify the governing payer or MAC diagnosis list.
M54.18	Radiculopathy, sacral and sacrococcygeal region.	Use only when the documented region and clinical findings support this level of specificity.
M51.17	Intervertebral disc disorder with radiculopathy, lumbosacral region.	Confirm the documented disc pathology, level, side, and imaging concordance.
M47.27	Other spondylosis with radiculopathy, lumbosacral region.	Requires radicular features; degenerative change or axial pain alone is insufficient.
M48.07	Spinal stenosis, lumbosacral region.	Document the relationship between stenosis and the requested sacral root; payer and MAC code-list inclusion varies.
M96.1	Postlaminectomy syndrome, not elsewhere classified.	A postoperative diagnosis alone does not establish the current sacral radicular generator.
Other supported diagnosis	Use the most specific diagnosis supported by the clinical record and accepted by the governing policy.	Never select or alter a diagnosis solely to obtain authorization or payment.

Crosswalk Rule Never maintain one national "approved ICD list" for sacral TFESI. Maintain a payer- and MAC-specific diagnosis matrix with effective dates and source links.

Back to procedure navigation

25

Procedure Library

Modifiers, Units, NCCI, MUE, and Place of Service

Issue	Operational standard
Modifier 50	Use for bilateral professional billing only when the payer directs. Verify whether the payer expects one line or another format.
RT/LT	May be required by payer or setting. ASC claims may require separate RT and LT lines rather than modifier 50.
KX	Use only when the governing MAC article directs it for a diagnostic selective nerve root block and the service meets that definition.
Units	64483 is generally one unit for the first level. 64484 reflects an additional level. Bilateral reporting rules vary and do not automatically justify extra units.
NCCI	Image guidance is integral. Review current NCCI edits for same-day spinal injections, sedation, and other services. Do not unbundle.
MUE	Verify the current CMS or payer MUE and adjudication indicator. Do not hard-code an MUE value into a permanent workflow without version control.
POS 11	Office reimbursement and medication reporting depend on payer and supply arrangements.
POS 22	Hospital outpatient authorization must match the facility and professional service requirements.
POS 24	ASC claims require setting-specific modifier, bilateral, drug, and facility rules.
One region per session	Aligned Medicare LCDs limit treatment to one spinal region per session.
Same-day combinations	Multiple block types are generally restricted under Medicare and UM policies, with narrow exceptions such as certain synovial cyst scenarios.

Back to procedure navigation

26

Procedure Library

Reimbursement Considerations

Reimbursement varies by payer, locality, contract, site of service, provider type, bilateral method, number of authorized levels, medication supply, and claim edits. A national fee amount should not be presented as the expected payment. Instead, the organization should maintain a payer- and site-specific reimbursement matrix.

• Professional versus facility payment. Office, ASC, and hospital outpatient claims have different payment structures and authorization dependencies.
• Add-on code integrity. 64484 should be reimbursed only when an additional level was performed, medically necessary, documented, authorized, and correctly linked to 64483.
• Bilateral methodology. Payers may apply bilateral reductions or alternative line-item processing. Contract modeling should reflect the payer's actual method.
• Drug reimbursement. Confirm whether medication is separately billable, bundled, supplied by the facility, or subject to J-code, wastage, or invoice rules.
• Authorization linkage. A valid authorization may still deny if the claim has a different level count, laterality, provider, facility, site, or date.
• Post-payment exposure. High-volume TFESI can attract data analysis, utilization review, and medical-record audit even when prior authorization was not required.
• Revenue forecasting. Forecast using allowed amounts and adjudicated history, not billed charges or a national average.
• Underpayment review. Compare the remittance to the contract, bilateral method, add-on code logic, and authorization before writing off a variance.

Back to procedure navigation

27

Procedure Library

Integrated Compliance and Quality Controls

Control	Owner	Evidence retained
Policy currency check	Prior authorization lead	Policy title, ID, version, effective date, access date, and URL.
Clinical coherence review	Physician/APP and clinical reviewer	Root, level, side, symptoms, examination, imaging, route rationale, and plan.
Frequency ledger	Authorization or UM team	All regional ESI sessions across providers and approaches when available.
Authorization reconciliation	Scheduling and billing	Authorized versus scheduled versus performed code, level, side, provider, site, and date.
Procedure-note completeness	Clinical operations	Image guidance, contrast, level, side, injectate, findings, complications, and purpose.
Outcome capture	Clinical team	Same pain/function scale, percentage improvement, duration, function, and medication change.
Claim edit	Coding/billing	Code family, add-on logic, modifiers, units, POS, drug reporting, and NCCI review.
Denial learning	RCM and leadership	Root cause, payer, policy, preventability, appeal result, corrective action, and trend.

Back to procedure navigation

28

Procedure Library

Denial Prevention

• Build from the physician note. Do not ask authorization staff to invent route rationale, neurologic findings, or imaging concordance.
• Use a root-level summary. A concise table of root, level, side, symptom, exam, and MRI finding reduces reviewer inference.
• Submit dated conservative care. Generic language such as "failed PT" is a common preventable deficiency.
• Verify the diagnosis list. The correct clinical diagnosis may still be absent from a particular MAC article or plan list.
• Count regional sessions. Include caudal and interlaminar injections in the lumbar/sacral tally.
• Validate +64484. A second level must be clinically necessary, supported, requested, and authorized.
• Reconcile laterality. Right/left/bilateral discrepancies should stop the workflow before service or claim submission.
• Do not overstate evidence. Use the disc-herniation evidence for disc herniation and the more limited stenosis evidence for stenosis.
• Measure repeat outcomes. Percent improvement without duration or functional effect is often insufficient.
• Save the policy. A screenshot or copied criterion without source, version, and date is weak audit evidence.

Back to procedure navigation

29

Procedure Library

Common Denial Reasons

Denial reason	Root cause	Corrective action
No medical necessity	Generic low-back pain, nonconcordant findings, or missing route rationale.	Strengthen clinical documentation before resubmission; do not merely change the diagnosis code.
Imaging mismatch	Requested level/side does not match the MRI or clinical pattern.	Physician review and corrected order, rationale, or alternative plan.
Insufficient conservative care	No dates, duration, adherence, outcome, or exception.	Submit contemporaneous treatment records and a concise chronology.
Frequency exceeded	Prior ESI sessions were counted by code instead of region.	Reconstruct the regional ledger and verify the look-back period.
Second level unsupported	+64484 requested without distinct clinical and imaging support.	Document each level or remove the unsupported level.
Repeat threshold not met	Prior response lacks required percentage, function, or duration.	Use the same baseline/follow-up measure; appeal only when the actual record meets policy.
Authorization mismatch	Performed service differs by route, level, side, provider, site, or date.	Amend or obtain new authorization when possible; reconcile before billing.
Noncovered diagnosis	ICD code absent from the governing list or does not support the service.	Verify the correct supported diagnosis; do not upcode or substitute inaccurately.
Sedation denial	Routine sedation billed without a patient-specific exception.	Review medical necessity and payer policy; correct the claim when unsupported.
KX misuse	Diagnostic SNRB modifier appended to a therapeutic TFESI or without required documentation.	Correct coding and educate the clinical/coding team.

Back to procedure navigation

30

Procedure Library

Appeals and Peer-to-Peer Review

An effective appeal is policy-specific and evidence-disciplined. It should not be a generic letter describing how common sacral TFESI is. The appeal must identify the denied criterion, show where the record satisfies it, address the reviewer's actual concern, and use diagnosis-appropriate evidence.

Appeal structure

1. Identify the member, requested code(s), level(s), side(s), date, denial reference, and governing policy.

2. Quote or accurately paraphrase the exact denial criterion.

3. Provide a concise clinical summary: named root, symptom distribution, objective findings, imaging lesion, functional impairment, and prior care.

4. Explain why the transforaminal route is appropriate for this patient.

5. For a second level, justify each level separately.

6. For a repeat, quantify prior pain and functional improvement and duration using the same scale when required.

7. Address regional frequency history and any same-day procedure issue.

8. Use evidence matched to the diagnosis: disc-herniation evidence for disc herniation; a more restrained argument for stenosis.

9. Request a clear determination and preserve the appeal record, call reference, reviewer name, and deadline.

Peer-to-peer preparation card

Question likely to be asked	Prepared response should contain
What is the diagnosis and root?	Specific diagnosis, named root, symptom pattern, and objective findings.
What does the imaging show?	Date, modality, lesion, level, side, and clinical concordance.
Why transforaminal?	Patient-specific targeted-route rationale and alternative approaches considered.
What conservative care failed?	Dated treatments, participation, outcome, intolerance, or exception.
Why two levels or bilateral?	Distinct symptoms/findings and imaging support for each level and side.
What happened after the prior injection?	Percentage pain and function improvement, duration, activity and medication changes.
How many ESIs occurred in the region?	Complete regional session count across approaches.
What is the next step?	Rehabilitation, diagnostic clarification, medication reduction, surgical decision, or another defined objective.

Back to procedure navigation

31

Procedure Library

Operational Workflow

Stage	Required action	Failure prevented
Referral/intake	Capture exact procedure, code family, levels, laterality, diagnosis, payer, and requested site.	Wrong authorization pathway or incomplete order.
Benefits/delegation	Verify benefit, network, delegated reviewer, and code scope.	Submitting to the wrong entity or missing authorization.
Clinical readiness	Check symptoms, exam, imaging, conservative care, function, route rationale, and history.	Medical-necessity denial or peer-to-peer.
Policy review	Apply the live payer/MAC policy and record source metadata.	Use of outdated or noncontrolling criteria.
Submission	Send a concise, indexed, code- and level-specific package.	Reviewer inference and missing records.
Scheduling	Match authorization to provider, site, date range, route, level, side, and units.	Day-of-service cancellation or claim mismatch.
Procedure documentation	Record the performed level/side, image guidance, contrast, injectate, purpose, and outcome plan.	Coding ambiguity and post-payment risk.
Charge capture	Validate 64483/+64484, modifiers, units, drug, POS, and authorization.	Clean-claim denial or underpayment.
Follow-up	Measure pain, function, duration, medication use, and next plan.	Unsupported repeat request.
Governance	Trend approvals, denials, peer-to-peer, frequency, outcomes, and revenue leakage.	Repeated systemic failure.

Back to procedure navigation

32

Procedure Library

Payer Perspective

A payer or UM reviewer is testing diagnostic confidence, anatomic concordance, treatment sequencing, duplication, frequency, expected benefit, and risk. The reviewer will ask whether a targeted transforaminal route is necessary when other epidural approaches exist, whether the requested second level or bilateral service is separately supported, and whether the prior response justifies another exposure.

The strongest request reduces uncertainty. It does not overwhelm the reviewer with an entire chart. It identifies the governing criterion and provides the exact clinical evidence that satisfies it.

Back to procedure navigation

33

Procedure Library

Clinical Pearls

• Disc herniation and stenosis are not the same evidence case. The literature supports stronger claims for disc-herniation radicular pain than for stenosis.
• A targeted route requires a targeted record. The more specific the procedure, the more specific the clinical story should be.
• Do not use imaging in isolation. A common asymptomatic abnormality becomes relevant only through clinical correlation.
• An early repeat is not a routine series. When allowed, it requires a changed plan and documented rationale.
• Bilateral is not synonymous with two levels. Laterality and level count are separate concepts for authorization and billing.
• Non-particulate initial injectate is a consensus safeguard, not an absolute FDA prohibition. Document the clinician's injectate decision and rationale under current standards.
• Temporary benefit can be clinically meaningful. The goal should connect symptom reduction to measurable function, rehabilitation, or decision-making rather than promise durable cure.

Back to procedure navigation

34

Procedure Library

GoHealthcare Perspective

Sacral TFESI is a high-value test of an organization's operational maturity because clinical specificity and revenue-cycle specificity are inseparable. A practice may perform the procedure correctly and still lose authorization or payment when the level, side, diagnosis, route, code, and outcome history are not synchronized across systems.

The best operating model creates one structured episode record that follows the case from clinical decision through authorization, scheduling, procedure, coding, adjudication, follow-up, and future utilization review. This reduces duplicate work, protects clinical integrity, and produces data leadership can use.

Back to procedure navigation

35

Procedure Library

GoHealthcare Insights

• Create a level-and-side authorization object. Do not manage TFESI as a generic "lumbar epidural" task.
• Build a regional ESI ledger. Count every lumbar/sacral epidural session across approaches and locations.
• Separate initial and repeat templates. Repeat cases require a different data set centered on measured response and duration.
• Build a MAC-specific ICD matrix. The M48.07 difference between A56651 and A58995 illustrates why a national static list fails.
• Add a route-rationale field to physician documentation. This prevents authorization teams from constructing clinical reasoning after the visit.
• Use policy-effective-date alerts. eviCore's published future version demonstrates the need to distinguish publication date from effective date.
• Reconcile before service and before claim. A two-stage control catches authorization drift and charge-capture drift.
• Measure avoidable peer-to-peer rate. Peer-to-peer review should be analyzed as a workflow defect when the missing criterion was available before submission.
• Use denials as policy intelligence. Code each denial by root cause, policy clause, payer, reviewer, and preventability.

Back to procedure navigation

36

Procedure Library

Key Takeaways

1. Sacral TFESI is a level- and laterality-specific epidural procedure reported with CPT 64483 and add-on 64484 for an additional level.

2. T12-L1 TFESI is reported with 64479 under MAC billing guidance.

3. The strongest coverage and evidence position is a concordant lumbar disc herniation with radicular pain or radiculopathy.

4. Spinal stenosis has a more limited evidence position and requires disciplined outcome claims and route rationale.

5. Medicare generally limits TFESI to two total levels per session and four ESI sessions per region in a rolling 12 months.

6. Lumbar interlaminar, caudal, and lumbar/sacral transforaminal sessions must be counted together for regional limits.

7. Covered ICD-10-CM codes vary by MAC article; M48.07 is a prominent example.

8. Commercial payer and delegated UM thresholds differ materially, especially for imaging, conservative care, repeat response, and frequency.

9. An automatic series of three is not supported operationally.

10. The order, authorization, procedure note, claim, and follow-up must tell the same root-level story.

Back to procedure navigation

37

Procedure Library

Frequently Asked Questions

What code is used for a single-level sacral TFESI?

CPT 64483 is the primary code for a lumbar or sacral transforaminal injection at a single level with fluoroscopy or CT.

What code is used for a second lumbar or sacral level?

Add-on CPT 64484 may be reported for an additional medically necessary level when performed and supported. It is not reported alone.

How is an S1 transforaminal injection coded?

An S1 transforaminal epidural injection is reported from the lumbar/sacral transforaminal code family. CPT 64483 is used for the first lumbar or sacral level, with add-on CPT 64484 for each additional lumbar or sacral level when applicable. Verify payer edits, authorization, laterality reporting, and the operative record.

Can sacral TFESI be bilateral?

Yes, when clinically indicated, documented, authorized, and reported according to the payer and site-of-service billing rules.

Does bilateral mean two levels?

No. Bilateral refers to right and left at a level; level count is a separate authorization and coding concept.

How many levels can Medicare cover in one session?

Aligned Medicare LCDs generally allow no more than two total transforaminal levels in one spinal region per session.

How many sessions can Medicare cover?

Aligned LCDs generally limit ESIs to four sessions per spinal region in a rolling 12-month period, subject to all medical-necessity requirements.

Do caudal and interlaminar injections count toward the same limit?

Yes. The regional limit generally counts all ESI approaches in the lumbar/sacral region.

Is an MRI always required?

Requirements vary. For sacral TFESI, major payer and UM policies generally expect advanced imaging that correlates with the targeted root; Medicare requires concordant radiological testing and image guidance for the procedure.

Is four weeks of conservative care always required?

It is a common requirement. Policy-defined exceptions may apply, such as objective radiculopathy under Carelon or acute zoster under Medicare, but they must be documented.

What is required for a repeat under Medicare?

Generally >=50% sustained improvement in pain and/or function for at least three months using the same scale, with a limited pathway for a changed-plan repeat after 14 days when the initial injection underperforms.

Can a diagnostic selective nerve root block use the same code?

Yes. The same code family may be used, but purpose and documentation differ. Certain MAC articles instruct use of modifier KX for diagnostic SNRB.

Is fluoroscopy separately billable?

No. Fluoroscopy or CT guidance is included in CPT 64483/64484.

Is ultrasound appropriate for routine sacral TFESI billing?

Major policies generally require fluoroscopy or CT with contrast. Limited exceptions may exist for documented contraindications; verify the governing policy.

Does WISeR apply to 64483?

CMS Guide Version 6.0 is internally inconsistent: its narrative says the ESI review applies to 62323 only, while an appendix table lists 64483/64484. Verify live WISeR code applicability before service in a model state.

Does authorization guarantee payment?

No. Payment still depends on eligibility, benefit coverage, network, site, provider, coding, documentation, claim edits, and authorization compliance.

What is the most preventable denial?

A mismatch among the requested root, level, laterality, imaging, authorization, and performed service is one of the most preventable failures.

What should happen if the route or level changes on the procedure date?

Pause and verify whether the payer permits an amendment or requires a new authorization. Reconcile before claim release.

Back to procedure navigation

38

Procedure Library

Related Procedures

• Lumbar Interlaminar Epidural Steroid Injection
• Caudal Epidural Steroid Injection
• Thoracic Transforaminal Epidural Steroid Injection
• Cervical Transforaminal Epidural Steroid Injection
• Diagnostic Selective Nerve Root Block
• Percutaneous Epidural Adhesiolysis / Neuroplasty
• Lumbar Medial Branch Block
• Lumbar Radiofrequency Ablation
• Sacroiliac Joint Injection
• Minimally Invasive Lumbar Decompression
• Interspinous Spacer Procedures
• Spinal Cord Stimulator Trial and Implant

GoHealthcare Case Study Library

Review operational case studies at https://www.gohealthcarellc.com/case-studies.html

Back to procedure navigation

39

Procedure Library

References and Policy Sources

Policies and codes must be reverified for the member, product, jurisdiction, site of service, and date of service. Accessed July 27, 2026 unless otherwise stated.

1. Centers for Medicare & Medicaid Services. LCD L36920, Epidural Steroid Injections for Pain Management. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=36920

2. Centers for Medicare & Medicaid Services. Billing and Coding Article A56651, Epidural Steroid Injections for Pain Management. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=56651

3. Centers for Medicare & Medicaid Services. Billing and Coding Article A58995, Epidural Steroid Injections for Pain Management. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=58995

4. Centers for Medicare & Medicaid Services. Billing and Coding Article A56681, Epidural Steroid Injections for Pain Management. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=56681

5. Centers for Medicare & Medicaid Services. LCD L39240, Epidural Steroid Injections for Pain Management. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39240

6. Centers for Medicare & Medicaid Services. LCD L33906, Epidural Steroid Injections for Pain Management. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33906

7. Centers for Medicare & Medicaid Innovation. WISeR Model Provider and Supplier Operational Guide, Version 6.0, April 24, 2026. https://www.cms.gov/priorities/innovation/files/wiser-provider-supplier-guide.pdf

8. UnitedHealthcare. Epidural Steroid Injections for Spinal Pain, Commercial and Individual Exchange Medical Policy, effective June 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/epidural-steroid-injections-spinal-pain.pdf

9. Aetna. Clinical Policy Bulletin 0722, Transforaminal Epidural Injections. https://www.aetna.com/cpb/medical/data/700_799/0722.html

10. Aetna. Clinical Policy Bulletin 0016, Back Pain - Invasive Procedures. https://www.aetna.com/cpb/medical/data/1_99/0016.html

11. Carelon Medical Benefits Management. Interventional Pain Management Clinical Guidelines, effective June 14, 2026. https://guidelines.carelonmedicalbenefitsmanagement.com/interventional-pain-management-2026-06-14/

12. eviCore by Evernorth / Cigna. CMM-200 Epidural Steroid Injections, effective February 25, 2026. https://www.evicore.com/sites/default/files/clinical-guidelines/2026-02/Cigna_Epidural%20Steroid%20Inj%20%28CMM-200%29_V1.1.2025_Eff02.25.2026_pub01.30.2026_upd02.13.2026.pdf

13. eviCore by Evernorth / Cigna. CMM-200 Epidural Steroid Injections, published for effective date August 4, 2026. https://www.evicore.com/sites/default/files/clinical-guidelines/2026-04/Cigna_CMM-200%20Epidural%20Steroid%20Inj_V1.0.2026_Eff08.04.2026_Pub04.17.2026.pdf Future-effective as of the policy currency date.

14. Evolent / RadMD. Clinical guidelines and provider resources for delegated utilization management. https://www1.radmd.com/ Plan-specific access may be required.

15. Cohere Health. Delegated Musculoskeletal Care Management. https://www.coherehealth.com/utilization-management/delegated/musculoskeletal-care-management Plan-specific workflow applies.

16. Blue Cross and Blue Shield of North Carolina. Epidural Steroid Injections policy archive and Carelon transition information. https://www.bluecrossnc.com/providers/policies-guidelines-codes/commercial/medical/updates/epidural-steroid-injections

17. Armon C, et al.. Epidural Steroids for Cervical and Lumbar Radicular Pain and Spinal Stenosis: Systematic Review Summary. Neurology. 2025;104(5):e213361. https://pubmed.ncbi.nlm.nih.gov/39938000/

18. Manchikanti L, et al.. Epidural Interventions in the Management of Chronic Spinal Pain: ASIPP Comprehensive Evidence-Based Guidelines. Pain Physician. 2021;24(S1):S27-S208. https://www.painphysicianjournal.com/current/pdf/NzIwNQ%3D%3D/133

19. Helm S, et al.. Transforaminal Epidural Steroid Injections: A Systematic Review and Meta-Analysis of Efficacy and Safety. Pain Physician. 2021. https://www.painphysicianjournal.com/current/pdf?article=NzIwNg%3D%3D&journal=133

20. U.S. Food and Drug Administration. Drug Safety Communication: rare but serious neurologic problems after epidural corticosteroid injections. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-requires-label-changes-warn-rare-serious-neurologic-problems-after

21. Rathmell JP, et al.. Safeguards to Prevent Neurologic Complications after Epidural Steroid Injections. Anesthesiology. 2015;122(5):974-984. https://pubmed.ncbi.nlm.nih.gov/25668411/

22. Blackham KA, et al.. ACR-ASNR-ASSR-SIR-SNIS Practice Parameter for the Performance of Image-Guided Epidural Steroid Injection. AJNR Am J Neuroradiol. 2026;47(6):1433-1447. doi:10.3174/ajnr.A9280. https://pubmed.ncbi.nlm.nih.gov/42235968/

23. Narouze S, et al.. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications, Second Edition. Regional Anesthesia and Pain Medicine. 2018;43(3):225-262. https://rapm.bmj.com/content/43/3/225

24. GoHealthcare Practice Solutions. Case Study Library. https://www.gohealthcarellc.com/case-studies.html

25. GoHealthcare Practice Solutions. Company website and published performance metrics. https://www.gohealthcarellc.com/ Company-reported metrics; results vary.

CMS Medicare Coverage Database. Epidural Steroid Injections for Pain Management, LCD L36920. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=36920

CMS Medicare Coverage Database. Billing and Coding: Epidural Steroid Injections for Pain Management, Article A56681. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=56681

CMS Medicare Coverage Database. Billing and Coding: Epidural Steroid Injections for Pain Management, Article A58995. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=58995

UnitedHealthcare. Epidural Steroid Injections for Spinal Pain. 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/epidural-steroid-injections-spinal-pain.pdf

Carelon Medical Benefits Management. Interventional Pain Management Guidelines. Effective June 14, 2026. https://guidelines.carelonmedicalbenefitsmanagement.com/interventional-pain-management-2026-06-14/

EviCore by Evernorth. CMM-200 Epidural Steroid Injections. 2026. https://www.evicore.com/

U.S. Food and Drug Administration. Drug Safety Communication: rare but serious neurologic problems after epidural corticosteroid injections. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-requires-label-changes-warn-rare-serious-neurologic-problems-after

GoHealthcare Practice Solutions Case Study Library. https://www.gohealthcarellc.com/case-studies.html

Back to procedure navigation

40

Procedure Library

Disclaimer

Professional, Clinical, Coding, and Policy Disclaimer This resource is provided for healthcare operations, education, and general informational purposes. It does not constitute medical, legal, coding, billing, reimbursement, compliance, payer-contract, or utilization-review advice; establish a standard of care; guarantee coverage, authorization, payment, or outcome; or replace professional judgment, current licensed codebooks, official CMS instructions, the applicable MAC LCD and billing article, member-specific benefit documents, commercial payer policies, delegated UM criteria, contracts, statutes, regulations, or facility policy. Policies, codes, and payment rules change. Users must verify every requirement directly for the patient, payer, product, jurisdiction, provider, site of service, and date of service. Clinical decisions remain the responsibility of qualified treating professionals.

Request Help

GoHealthcare Practice Solutions helps MSK specialty organizations strengthen prior authorization, utilization management, clinical documentation, payer-policy operations, coding integrity, denial prevention, and revenue-cycle execution.

Request Help: https://www.gohealthcarellc.com/contact-us.html

Case Study Library: https://www.gohealthcarellc.com/case-studies.html

Developed by GoHealthcare Practice Solutions for the GoHealthcare MSK Specialty Procedure Library.

Back to procedure navigation

Strengthen Sacral Transforaminal ESI Authorization and Revenue Integrity

GoHealthcare supports medical-necessity review, prior authorization, utilization management, clinical documentation alignment, denial prevention, appeals, and reimbursement operations for musculoskeletal specialty practices and healthcare organizations.

Request HelpView Case Studies

Case Study Library: https://www.gohealthcarellc.com/case-studies.html